Bristol-Myers-Celgene acquisition is just the start of pharmaceutical industry mergers, says analyst

CNBC's "Squawk on the Street" discusses a deal between Bristol-Myers and Celgene with Brian Skorney, senior biotech analyst at Baird, and Geoffrey Porges, director of therapeutics research and senior analyst at Leerink Partners.
Thu, Jan 3 201910:30 AM EST